Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3687

Sort by

Sort Order Select

Journal Articles

CML: new tools to answer old questions

George Giotopoulos, Brian J. P. Huntly

Blood (2020) 135 (26): 2327–2328.

https://doi.org/10.1182/blood.2020005599

Published: 2020

Journal Articles

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Junjing Qiao, MD PhD, Dandan Zhao, MD, Le Xuan Truong Nguyen, PhD, Herman Wu, BS, Gang Liu, PhD, Shanshan Suo, MD, Huafeng Wang, Yasmin Elhajmoussa, Chen Liang, MD, David Snyder, MD, Haris Ali, MD, Steven Rosen, MD, Nadia Carlesso, MD, Ling Li, PhD, Ya-Huei Kuo, PhD, Guido Marcucci, MD, Bin Zhang, PhD

Blood (2019) 134 (Supplement_1): 3791.

https://doi.org/10.1182/blood-2019-127616

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Jeremy Chang, MD, Sherry Zhang, MD, Mojtaba Akhtari, MD

Blood (2019) 134 (Supplement_1): 2581.

https://doi.org/10.1182/blood-2019-123738

Published: 2019

Journal Articles

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

Zhang Guang ji, Sr., master, Jianxiang Wang, MD, Ying Wang, Hui Wei, MD, Yingchang Mi, MD

Blood (2019) 134 (Supplement_1): 2583.

https://doi.org/10.1182/blood-2019-126480

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 2933.

https://doi.org/10.1182/blood-2019-131454

Published: 2019

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Peter Müller, PhD, Bärbel Edelmann-Stephan, PhD, Fabian Richter, PhD, Klaus Pfizenmaier, PhD, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2966.

https://doi.org/10.1182/blood-2019-127997

Published: 2019

Journal Articles

Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation

Monica Bocchia, Anna Sicuranza, PhD, Paola Pacelli, PhD, Patrizia Pregno, Mario Annunziata, Federica Sorà, MD, Elisabetta Abruzzese, MD, Monica Crugnola, MD, Luigiana Luciano, MD, Alessandra Iurlo, MD, Sara Galimberti, MD PhD, Anna Marina Liberati, Ilaria Ferrigno, PhD, Sara Ciofini, Marzia Defina, Luca Puccetti, Donatella Raspadori, PhD

Blood (2019) 134 (Supplement_1): 2919.

https://doi.org/10.1182/blood-2019-122814

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 3382.

https://doi.org/10.1182/blood-2019-131207

Published: 2019

Journal Articles

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Haruka Hiroki, MD, Masatoshi Takagi, MD PhD, Yuko Ishi, MD, Jinhua Piao, Tomohiro Morio, MD PhD

Blood (2019) 134 (Supplement_1): 3367.

https://doi.org/10.1182/blood-2019-127853

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CML: new tools to answer old questions

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2 +/V617F Mice

Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only